Press Releases

Date Title and Summary Additional Formats
Toggle Summary Harvard Bioscience Schedules Third Quarter 2019 Earnings Conference Call for November 5 at 4:30 PM ET
HOLLISTON, Mass. , Oct. 22, 2019 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its quarterly results for third quarter ended September 30, 2019 after market close on November 5, 2019 and hold a conference call to discuss the results for the third quarter on November 5,
View HTML
Toggle Summary Harvard Bioscience Announces Executive Appointment
HOLLISTON, Mass. , Oct. 21, 2019 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) announced today that Ken Olson has been named Vice President and General Manager, Pre-Clinical Systems (DSI), reporting to Chairman, President and CEO, Jim Green .
View HTML
Toggle Summary Harvard Bioscience Announces Strategic Action Plan and Financial Targets
HOLLISTON, Mass. , Sept. 09, 2019 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announces its strategic action plan and financial targets for rest of year 2019 through 2021. Key strategic actions and financial targets to position Harvard Bioscience for long-term profitable
View HTML
Toggle Summary Harvard Bioscience Elects Alan Edrick to Board of Directors
HOLLISTON, Mass. , Sept. 04, 2019 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) announced today that its Board of Directors has elected Alan Edrick to Harvard Bioscience’s Board of Directors, effective September 3, 2019 . Bertrand Loy , Lead Independent Director, said “After
View HTML
Toggle Summary Harvard Bioscience to Present at Janney Healthcare Conference
HOLLISTON, Mass. , Sept. 04, 2019 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) announced that Chairman, President and CEO, Jim Green , will be presenting at the Janney Montgomery Scott Healthcare Conference in New York City on September 9, 2019 at 9:05 a.m. EDT .
View HTML
Toggle Summary Harvard Bioscience Announces Quarter Ended June 30, 2019 Financial Results
- GAAP and adjusted non-GAAP revenue of $29.6 million - GAAP and adjusted non-GAAP earnings per share of $(0.01) and $0.04 , respectively - 2019 guidance remains unchanged HOLLISTON, Mass. , July 25, 2019 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”), today announced
View HTML
Toggle Summary Harvard Bioscience Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
HOLLISTON, Mass. , July 19, 2019 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) announced today that in connection with Michael Rossi being named Chief Financial Officer on July 18, 2019 , the Compensation Committee of the Board of Directors approved the grant of equity awards to Mr.
View HTML
Toggle Summary Harvard Bioscience Schedules Second Quarter 2019 Earnings Conference Call for July 25 at 4:30 PM ET
HOLLISTON, Mass. , July 19, 2019 (GLOBE NEWSWIRE) -- Harvard Bioscience , Inc. (Nasdaq: HBIO) will announce its quarterly results for the second quarter ended June 30, 2019 after market close on July 25, 2019 and hold a conference call to discuss the results for the second quarter on July 25, 2019
View HTML
Toggle Summary Harvard Bioscience Names Michael Rossi Chief Financial Officer
HOLLISTON, Mass. , July 18, 2019 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) announced today that Michael Rossi has been named Chief Financial Officer, effective immediately.  Rossi most recently served as Chief Financial Officer of Laborie Medical Technologies , a global medical
View HTML
Toggle Summary James Green Named President and CEO of Harvard Bioscience
HOLLISTON, Mass. , July 08, 2019 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) announced today that James Green has been named President and Chief Executive Officer of the Company by its Board of Directors, effective immediately. Additionally, Harvard Bioscience’s Board has appointed
View HTML